Načítá se...
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
There is a pressing need for more effective therapies to treat patients with T-cell lymphomas (TCLs), including first-line approaches that increase the response rate to cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) chemotherapy. We characterized the mitochondrial apoptosis pathway...
Uloženo v:
| Vydáno v: | Blood |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Hematology
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6367646/ https://ncbi.nlm.nih.gov/pubmed/30498064 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-07-865527 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|